On Monday, DDR Corp (NYSE:DDR)’s shares inclined 0.25% to $15.89.
DDR Corp. (DDR) declared that it closed on the acquisition of two power centers and an adjoining outparcel valued at $111 million and the disposition of ten assets totaling $102 million at 100% ownership during the second quarter of 2015.
The Company attained Willowbrook Plaza, a 385,000-square-foot power center located in Houston, Texas. The asset is adjacent to Willowbrook Mall, one of Houston’s top performing malls, and presents noteworthy opportunity to drive occupancy and NOI growth given its current 87% leased rate. The asset also has the potential for at least 10,000 square feet of expansion. DDR also attained International Drive Value Center, a 186,000-square-foot power center located in Orlando, Florida. The center’s tenant lineup features a strong mix of national retailers, counting two of the highest-performing Ross Dress for Less and T.J. Maxx stores in each respective chain. The asset is located in a submarket with two of the nation’s most productive retail properties, the Mall at Millenia and Orlando International Premium Outlets. Year-to-date, the Company has attained $160 million of assets at DDR’s share.
DDR Corp. is an equity real estate investment trust. It invests in the real estate markets of the United States and Puerto Rico. The firm is in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. It formerly known as Developers Diversified Realty Corp. DDR Corp is based in Beachwood, Ohio.
Occidental Petroleum Corporation (NYSE:OXY)’s shares gained 0.16% to $73.43.
Occidental Petroleum Corporation (OXY) told regulators on Friday that a top executive, Willie Chiang, has suddenly quit - a month after Vicki Hollub was picked to eventually replace Chief Executive Steve Chazen
Hollub, a longtime Occidental employee, will become the first woman to head a major U.S. oil company. That is predictable to occur next year.
Chiang was the company’s executive vice president, operations, and had stated directly to Chazen.
Occidental Petroleum Corporation engages in the acquisition, exploration, and development of oil and gas properties in the United States and internationally. The company operates in three segments: Oil and Gas; Chemical; and Midstream, Marketing and Other. The Oil and Gas segment explores for, develops, and produces oil and condensate, natural gas liquids (NGLs), and natural gas. Its domestic oil and gas operations are located in Colorado, New Mexico, North Dakota, and Texas; and international oil and gas operations are located in Bahrain, Bolivia, Colombia, Iraq, Libya, Oman, Qatar, the United Arab Emirates, and Yemen.
At the end of Monday’s trade, PulteGroup, Inc. (NYSE:PHM)‘s shares surged 0.29% to $20.75.
ulteGroup, Inc. (PHM) declared that it will release its second quarter 2015 financial results before the market opens on Thursday, July 23, 2015. The Company will hold a conference call to talk about second quarter results that same day at 8:30 a.m. (ET).
PulteGroup, Inc., through its auxiliaries, engages in the homebuilding business; mortgage banking operations; and title operations in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on land.
Celgene Corporation (NASDAQ:CELG), ended its Monday’s trading session with 1.73% gain, and closed at $120.89.
Celgene Corporation (CELG) will host a conference call and live audio webcast on Thursday, July 23, 2015 at 9 a.m. ET to talk about second quarter 2015 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
